Arguments in Favor of Inhaled Corticosteroids in COPD by Phenotype Instead of by Severity;Corticoides inhalados en la EPOC por fenotipo en lugar de por gravedad. Argumentos a favor

Archivos de Bronconeumologia

Volumn 47, Issue 6, 2011, Pages 271-273

  Miravitlles, Marc ^a  

^a HOSPITAL CLÍNIC   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

GLUCOCORTICOID;

CHRONIC OBSTRUCTIVE LUNG DISEASE; DISEASE SEVERITY; EDITORIAL; HUMAN; PHENOTYPE;

EID: 79957999396     PISSN: 03002896     EISSN: 15792129     Source Type: Journal    
DOI: 10.1016/j.arbr.2011.01.003     Document Type: Article

References (32)

1. Peces-Barba G., Barberà J.A., Agustí A., Casanova C., Casas A., Izquierdo J.L., et al. Guía Clínica SEPAR-ALAT de diagnóstico y tratamiento de la EPOC. Arch Bronconeumol 2008, 44:271-281.
2. De Miguel Díez J., Calle Rubio M., Rodríguez Hermosa J.L., Alvarez-Sala J.L. Guidelines for the treatment of COPD. Hot Topics Respir Med 2007, 5:7-14.
3. Jones P.W., Willits L.R., Burge P.S., Calverley P.M.A. Disease severity and the effect of fluticasone propionate on chronic obstructive pulmonary disease exacerbations. Eur Respir J 2003, 21:68-73.
4. Fabbri L.M., Romagnoli M., Corbetta L., Casoni G., Busljetic K., Turato G., et al. Differences in airway inflammation in patients with fixed airflow obstruction due to asthma or chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2003, 167:418-424.
5. Barnes P.J., Ito K., Adcock I.M. Corticosteroid resistance in chronic obstructive pulmonary disease: inactivation of histone deacetylase. Lancet 2004, 363:731-733.
6. Miravitlles M., Morera J. It's time for an etiology-based definition of chronic obstructive pulmonary disease. Respirology 2007, 12:317-319.
7. Soriano J.B., Davis K.J., Coleman B., Visick G., Mannino D., Pride N.B. The proportional Venn diagram of obstructive lung disease. Chest 2003, 124:474-481.
8. Kerstjens H.A.M., Overbeek S.E., Schouten J.P., Brand P.L.P., Postma D.S. Airways hyperresponsiveness, bronchodilator response, allergy and smoking predict improvement in FEV1 during long-term inhaled conticosteroid treatment. Eur Respir J 1993, 6:868-876.
9. Weiner P., Weiner M., Azgad Y., Zamir D. Inhaled budesonide therapy for patients with stable COPD. Chest 1995, 108:1568-1571.
10. Leigh R., Pizzichini M.M.M., Morris M.M., Maltais F., Hargreave F.E., Pizzichini E. Stable COPD: predicting benefit from high-dose inhaled corticosteroid treatment. Eur Respir J 2006, 27:964-971.
11. Brightling C.E., McKenna S., Hardagon B., Birring S., Green R., Siva R., et al. Sputum eosinophilia and the short term response to inhaled mometasone in chronic obstructive pumonary disease. Thorax 2005, 60:193-198.
12. Bleecker E.R., Emmett A., Crater G., Knobil K., Kalberg C. Lung function and symptom improvement with fluticasone propionate/salmeterol and ipratropium bromide/albuterol in COPD: Response by beta-agonist reversibility. Pulm Pharmacol Ther 2008, 21:682-688.
13. Papi A., Romagnoli M., Baraldo S., Braccioni F., Guzzinati I., Saetta M., et al. Partial reversibility of airflow limitation and increased exhaled NO and sputum eosinophilia in chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2000, 162:1773-1777.
14. Leuppi J.D., Tandjung R., Anderson S.D., Stolz D., Brutsche M.H., Bingisser R., et al. Prediction of treatment-response to inhaled corticosteroids by mannitol-challenge test in COPD. A proof of concept. Pulm Pharmacol Ther 2005, 18:83-88.
15. Kunisaki K.M., Rice K.L., Janoff E.N., Rector T.S., Niewoehner D.E. Exhaled nitric oxide, systemic inflammation, and the spirometric response to inhaled fluticasone propionate in severe chronic obstructive pulmonary disease: a prospective study. Ther Adv Respir Dis 2008, 2:55-64.
16. Dummer J.F., Epton M.J., Cowan J.O., Cook J.M., Condliffe R., Landhuis E., et al. Predicting corticosteroid response in chronic obstructive pulmonary disease using exhaled nitric oxide. Am J Respir Crit Care Med 2009, 180:846-852.
17. Lehtimäki L., Kankaanranta H., Saarelainen S., Annila I., Aine T., Nieminen R., et al. Bronchial nitric oxide is related to symptom relief during fluticasone treatment in COPD. Eur Respir J 2010, 35:72-78.
18. Nieto A., Mazon A., Pamies R., Linana J.J., Lanuza A., Jiménez F.O., et al. Adverse effects of inhaled corticosteroids in funded and nonfunded studies. Arch Intern Med 2007, 167:2047-2053.
19. Miravitlles M., Brosa M., Velasco M., Crespo C., Gobartt E., González-Rojas N. An economic analysis of pharmacological treatment of COPD in Spain. Respir Med 2009, 103:714-721.
20. Calverley P.M.A., Burge P.S., Spencer S., Anderson J.A., Jones P.W. Bronchodilator reversibility testing in chronic obstructive pulmonary disease. Thorax 2003, 58:659-664.
21. Lee J.H., Lee Y.K., Kim E.K., Kim T.H., Huh J.W., Kim W.J., et al. Responses to inhaled long-acting beta-agonist and corticosteroid according to COPD subtype. Respir Med 2010, 104:542-549.
22. De Marco R., Accordini S., Cerveri I., Corsico A., Antó J.M., Künzli N., et al. Incidence of chronic obstructive pulmonary disease in a cohort of young adults according to the presence of chronic cough and phlegm. Am J Respir Crit Care Med 2007, 175:32-39.
23. Gibson P.G., Simpson J.L. The overlap syndrome of asthma and COPD: what are its features and how important is it?. Thorax 2009, 64:728-735.
24. O'Donnell D.E., Aaron S., Bourbeau J., Hernandez P., Marciniuk D.D., Balter M., et al. Canadian Thoracic Society recommendations for management of chronic obstructive pulmonary disease -2007 update. Can Respir J 2007, 14(Suppl B):5B-32B.
25. Ferguson G.T., Anzueto A., Fei R., Emmett A., Knobil K., Kalberg C. Effect of fluticasone propionate/salmeterol (250/50μg) or salmeterol (50μg) on COPD exacerbations. Respir Med 2008, 102:1099-1108.
26. Kardos P., Wencker M., Glaab T., Vogelmeier C. Impact of salmeterol/fluticasone propionate versus salmeterol on exacerbations in severe chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2007, 175:144-149.
27. Agarwal R., Aggarwal A.N., Gupta D., Jindal S.K. Inhaled corticosteroids vs placebo for preventing COPD exacerbations. A systematic review and metaregression of randomized controlled trials. Chest 2010, 137:318-325.
28. Miravitlles M. Tratamiento de la enfermedad pulmonar obstructiva crónica. Med Clin (Barc) 2005, 125:65-74.
29. Miravitlles M. Tratamiento individualizado de la EPOC: una propuesta de cambio. Arch Bronconeumol 2009, 45(Suppl5):27-34.
30. Anderson D., MacNee W. Targeted treatment in COPD: a multi-system approach for a multi-system disease. Int J Chron Obst Pulm Dis 2009, 4:321-335.
31. López-Campos J.L. Estrategias de tratamiento de la enfermedad pulmonar obstructiva crónica: una propuesta de sistematización. Arch Bronconeumol 2010, 46:617-620.
32. Siva R., Green R.H., Brightling C.E., Shelley M., Hargadon B., McKenna S., et al. Eosinophilic airway inflammation and exacerbations of COPD: a randomised controlled trial. Eur Respir J 2007, 29:906-913.